DE60127421D1 - Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen - Google Patents

Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen

Info

Publication number
DE60127421D1
DE60127421D1 DE60127421T DE60127421T DE60127421D1 DE 60127421 D1 DE60127421 D1 DE 60127421D1 DE 60127421 T DE60127421 T DE 60127421T DE 60127421 T DE60127421 T DE 60127421T DE 60127421 D1 DE60127421 D1 DE 60127421D1
Authority
DE
Germany
Prior art keywords
vaccines
haemophilus influenzae
lipopolysaccharide
haemophilus
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60127421T
Other languages
English (en)
Other versions
DE60127421T2 (de
DE60127421T8 (de
Inventor
James C Richards
Andrew Cox
Richard Moxon
Derek Institute Of Hood
Elke K H Schweda
Martin Mansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of DE60127421D1 publication Critical patent/DE60127421D1/de
Publication of DE60127421T2 publication Critical patent/DE60127421T2/de
Publication of DE60127421T8 publication Critical patent/DE60127421T8/de
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60127421T 2000-08-25 2001-08-27 Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen Expired - Fee Related DE60127421T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22785000P 2000-08-25 2000-08-25
US227850P 2000-08-25
PCT/CA2001/001225 WO2002016440A2 (en) 2000-08-25 2001-08-27 Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections

Publications (3)

Publication Number Publication Date
DE60127421D1 true DE60127421D1 (de) 2007-05-03
DE60127421T2 DE60127421T2 (de) 2007-11-29
DE60127421T8 DE60127421T8 (de) 2008-08-28

Family

ID=22854724

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127421T Expired - Fee Related DE60127421T8 (de) 2000-08-25 2001-08-27 Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen

Country Status (9)

Country Link
US (1) US7364739B2 (de)
EP (1) EP1313771B1 (de)
JP (1) JP2004506086A (de)
AT (1) ATE357461T1 (de)
AU (1) AU2001285633A1 (de)
CA (1) CA2420477A1 (de)
DE (1) DE60127421T8 (de)
ES (1) ES2284681T3 (de)
WO (1) WO2002016440A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020059A2 (en) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
EP1747262B1 (de) * 2004-05-14 2012-09-26 National Research Council Of Canada Konservierte innerer-kern-lipopolysaccharid-epitope als impfstoffkandidaten für mehrere spezies
US8795680B2 (en) * 2006-07-21 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
JP2008125425A (ja) * 2006-11-20 2008-06-05 Osaka Univ 核酸の増幅反応に用いる繰返し配列結合プライマー及びその利用
WO2008106763A1 (en) * 2007-03-08 2008-09-12 The Governors Of The University Of Alberta Bacterial endotoxin for the prevention of metabolic disorders and bacterial infections
WO2016007891A1 (en) * 2014-07-10 2016-01-14 University Of Iowa Research Foundation Vaccine for nontypeable haemophilus influenzae

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681026A1 (de) 1987-03-02 1995-11-08 Whitehead Institute For Biomedical Research Rekombinant-mykobakterielle Impfstoffe
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
ZA894589B (en) * 1989-02-09 1991-02-27 K Sudan Krishan Semi-flexible or flexible phenolic foam
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2097931C (en) 1990-12-18 2003-07-29 Samuel I. Miller, Iii Salmonella vaccines
WO1992021376A1 (en) 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE19844191A1 (de) * 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli
CA2355292C (en) * 1998-12-15 2007-02-06 Exiqon A/S Coupling of lipopolysaccharide-derived carbohydrates onto solid surfaces
JP2004520001A (ja) * 1999-05-18 2004-07-08 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 複合糖質の製造

Also Published As

Publication number Publication date
JP2004506086A (ja) 2004-02-26
ES2284681T3 (es) 2007-11-16
WO2002016440A2 (en) 2002-02-28
DE60127421T2 (de) 2007-11-29
CA2420477A1 (en) 2002-02-28
WO2002016440A9 (en) 2004-05-13
EP1313771A2 (de) 2003-05-28
ATE357461T1 (de) 2007-04-15
WO2002016440A8 (en) 2002-11-14
AU2001285633A1 (en) 2002-03-04
DE60127421T8 (de) 2008-08-28
EP1313771B1 (de) 2007-03-21
WO2002016440A3 (en) 2002-06-06
US20050153057A1 (en) 2005-07-14
US7364739B2 (en) 2008-04-29

Similar Documents

Publication Publication Date Title
DE60238471D1 (de) Proteosom-liposaccharid-vakzine-adjuvans
FI931169A0 (fi) Foerbaettrade vaccinkompositioner
BR0009163A (pt) Vacina
EA200801367A1 (ru) Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
TW200514569A (en) Vaccine composition
MX341760B (es) Vacuna del conjugado proteina - polisacarido meningococico, multivalente.
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
WO2002091998A3 (en) Novel meningitis conjugate vaccine
NO913812L (no) Oligosakkaridkonjugatvaksiner.
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
BR0310062A (pt) Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
HUP0301413A1 (hu) Vakcinakészítmények
WO2010141312A3 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
DE60127421T8 (de) Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
AU2003206532A1 (en) Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
MY125000A (en) Novel compositions
DE69936296D1 (de) Konjugat-impfstoffe zur vorbeugung der zahnkaries
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee